Biogen and Denali Therapeutics have officially discontinued their experimental Parkinson’s disease drug, BIIB122, after the treatment failed to meet its primary endpoint in a late-stage clinical trial. The decision, announced jointly by the two biotech firms, marks the end of a high-profile collaboration aimed at slowing the progression of the neurodegenerative disorder. The drug, designed to inhibit the LRRK2 enzyme linked to genetic forms of Parkinson’s, showed no statistically significant benefit over placebo in slowing motor decline. For the estimated one million Americans living with Parkinson’s, the failure represents another setback in the long and costly search for a disease-modifying therapy.
The partnership between Biogen and Denali, forged in 2020 with a potential value exceeding $2 billion, had raised hopes among researchers and patients alike. BIIB122 was one of the most advanced candidates targeting the LRRK2 pathway, which is implicated in both inherited and sporadic cases of Parkinson’s. The Phase 2b/3 trial enrolled over 600 participants across multiple countries, including several clinical sites in the western United States. Despite promising early-stage data, the final analysis showed no meaningful difference between the drug and placebo groups, leading both companies to conclude that further development was not warranted. Biogen will record a charge related to the program, while Denali will shift focus to other pipeline assets.
For Las Vegas, a city with a rapidly aging population and a growing number of residents diagnosed with Parkinson’s, the news carries particular weight. Local neurologists at the Cleveland Clinic Lou Ruvo Center for Brain Health, a major research hub in downtown Las Vegas, have been closely monitoring the trial’s progress. The failure of BIIB122 underscores the immense difficulty of translating genetic insights into effective treatments for a disease as complex as Parkinson’s. While the setback is discouraging, it also reinforces the need for continued investment in alternative approaches, including gene therapy and biomarker-driven trials, many of which are being conducted right here in Southern Nevada.
English (US)·